{
    "symbol": "BIIB",
    "slug": "biib",
    "display_name": "BIIB",
    "category": "stocks",
    "region": "US",
    "description": null,
    "url": "https://finscans.com/asset/biib",
    "lang": "en",
    "as_of": "2026-07-16T05:20:41+00:00",
    "stats_30d": {
        "total_signals": 1,
        "bullish": 0,
        "bearish": 1,
        "neutral": 0,
        "explicit": 1,
        "inferred": 0,
        "avg_impact": 9,
        "avg_confidence": 95,
        "last_signal_at": "2026-07-14 17:01:09",
        "article_count": 1
    },
    "top_catalysts": [
        {
            "text": "Alzheimer's tau trial failure published on July 14, 2026",
            "count": 1
        },
        {
            "text": "Biogen's tau therapy fails to meet primary endpoints",
            "count": 1
        }
    ],
    "top_risk_factors": [
        {
            "text": "Positive data from other Alzheimer's programs could offset the impact",
            "count": 1
        },
        {
            "text": "If the sell-off is viewed as overdone, value buyers might step in",
            "count": 1
        }
    ],
    "recent_signals": [
        {
            "signal_at": "2026-07-14 17:01:09",
            "sentiment": "Bearish",
            "impact_score": 9,
            "confidence_score": 95,
            "mention_type": "explicit",
            "timeframe": "intraday",
            "region": "US",
            "reasoning": "Biogen shares fell after a clinical trial for an Alzheimer's disease therapy targeting tau protein failed to meet primary endpoints. The disappointing data undermines confidence in the company's pipeline beyond its amyloid franchise and heightens uncertainty about future revenue growth in neuroscience.",
            "article": {
                "title": "Biogen Stock Plunges as Tau-Targeting Alzheimer's Therapy Misses Trial Endpoints",
                "url": "https://finscans.com/news/biogen-stock-plunges-as-tau-targeting-alzheimers-therapy"
            }
        }
    ]
}